Diana M Norden1, Donna O McCarthy2, Sabahattin Bicer3, Raymond D Devine4, Peter J Reiser3, Jonathan P Godbout5, Loren E Wold6. 1. Department of Neuroscience, The Ohio State University, United States. 2. College of Nursing, Marquette University, United States. 3. Division of Biosciences, College of Dentistry, The Ohio State University, United States. 4. Molecular, Cellular and Developmental Biology Graduate Program, The Ohio State University, United States. 5. Department of Neuroscience, The Ohio State University, United States; Institute for Behavioral Medicine Research, The Ohio State University, United States. 6. College of Nursing, The Ohio State University, United States; Department of Physiology and Cell Biology, The Ohio State University, United States. Electronic address: loren.wold@osumc.edu.
Abstract
AIMS: Cancer-related fatigue (CRF) is often accompanied by depressed mood, both of which reduce functional status and quality of life. Research suggests that increased expression of pro-inflammatory cytokines is associated with skeletal muscle wasting and depressive- and fatigue-like behaviors in rodents and cancer patients. We have previously shown that treatment with ibuprofen, a nonsteroidal anti-inflammatory drug, preserved muscle mass in tumor-bearing mice. Therefore, the purpose of the present study was to determine the behavioral effects of ibuprofen in a mouse model of CRF. MAIN METHODS: Mice were injected with colon-26 adenocarcinoma cells and treated with ibuprofen (10mg/kg) in the drinking water. Depressive-like behavior was determined using the forced swim test (FST). Fatigue-like behaviors were determined using voluntary wheel running activity (VWRA) and grip strength. The hippocampus, gastrocnemius muscle, and serum were collected for cytokine analysis. KEY FINDINGS: Tumor-bearing mice showed depressive-like behavior in the FST, which was not observed in mice treated with ibuprofen. VWRA and grip strength declined in tumor-bearing mice, and ibuprofen attenuated this decline. Tumor-bearing mice had decreased gastrocnemius muscle mass and increased expression of IL-6, MAFBx and MuRF mRNA, biomarkers of protein degradation, in the muscle. Expression of IL-1β and IL-6 was also increased in the hippocampus. Treatment with ibuprofen improved muscle mass and reduced cytokine expression in both the muscle and hippocampus of tumor-bearing mice. SIGNIFICANCE: Ibuprofen treatment reduced skeletal muscle wasting, inflammation in the brain, and fatigue- and depressive-like behavior in tumor-bearing mice. Therefore, ibuprofen warrants evaluation as an adjuvant treatment for CRF.
AIMS: Cancer-related fatigue (CRF) is often accompanied by depressed mood, both of which reduce functional status and quality of life. Research suggests that increased expression of pro-inflammatory cytokines is associated with skeletal muscle wasting and depressive- and fatigue-like behaviors in rodents and cancerpatients. We have previously shown that treatment with ibuprofen, a nonsteroidal anti-inflammatory drug, preserved muscle mass in tumor-bearingmice. Therefore, the purpose of the present study was to determine the behavioral effects of ibuprofen in a mouse model of CRF. MAIN METHODS:Mice were injected with colon-26 adenocarcinoma cells and treated with ibuprofen (10mg/kg) in the drinking water. Depressive-like behavior was determined using the forced swim test (FST). Fatigue-like behaviors were determined using voluntary wheel running activity (VWRA) and grip strength. The hippocampus, gastrocnemius muscle, and serum were collected for cytokine analysis. KEY FINDINGS:Tumor-bearingmice showed depressive-like behavior in the FST, which was not observed in mice treated with ibuprofen. VWRA and grip strength declined in tumor-bearingmice, and ibuprofen attenuated this decline. Tumor-bearingmice had decreased gastrocnemius muscle mass and increased expression of IL-6, MAFBx and MuRF mRNA, biomarkers of protein degradation, in the muscle. Expression of IL-1β and IL-6 was also increased in the hippocampus. Treatment with ibuprofen improved muscle mass and reduced cytokine expression in both the muscle and hippocampus of tumor-bearingmice. SIGNIFICANCE: Ibuprofen treatment reduced skeletal muscle wasting, inflammation in the brain, and fatigue- and depressive-like behavior in tumor-bearingmice. Therefore, ibuprofen warrants evaluation as an adjuvant treatment for CRF.
Authors: Ann M Berger; Amy Pickar Abernethy; Ashley Atkinson; Andrea M Barsevick; William S Breitbart; David Cella; Bernadine Cimprich; Charles Cleeland; Mario A Eisenberger; Carmen P Escalante; Paul B Jacobsen; Phyllis Kaldor; Jennifer A Ligibel; Barbara A Murphy; Tracey O'Connor; William F Pirl; Eve Rodler; Hope S Rugo; Jay Thomas; Lynne I Wagner Journal: J Natl Compr Canc Netw Date: 2010-08 Impact factor: 11.908
Authors: Diana M Norden; Raymond Devine; Sabahattin Bicer; Runfeng Jing; Peter J Reiser; Loren E Wold; Jonathan P Godbout; Donna O McCarthy Journal: Physiol Behav Date: 2014-12-30
Authors: Lobna A Saleh; May Hamza; Nesreen H El Gayar; Abeer A Abd El-Samad; Essam A Nasr; Somaia I Masoud Journal: Pharmacol Biochem Behav Date: 2014-08-04 Impact factor: 3.533
Authors: Olga Husson; Willy-Anne Nieuwlaat; Wilma A Oranje; Harm R Haak; Lonneke V van de Poll-Franse; Floortje Mols Journal: Thyroid Date: 2013-07-25 Impact factor: 6.568
Authors: Theodore P Braun; Xinxia Zhu; Marek Szumowski; Gregory D Scott; Aaron J Grossberg; Peter R Levasseur; Kathryn Graham; Sheehan Khan; Sambasivarao Damaraju; William F Colmers; Vickie E Baracos; Daniel L Marks Journal: J Exp Med Date: 2011-11-14 Impact factor: 14.307
Authors: Elisabeth G Vichaya; Bianca G Ford; Jessica M Moltenkine; Cullen M Taniguchi; A Phillip West; Robert Dantzer Journal: Brain Behav Immun Date: 2021-08-19 Impact factor: 7.217
Authors: Jonathan Savitz; Bart N Ford; Rayus Kuplicki; Sahib Khalsa; T Kent Teague; Martin P Paulus Journal: Psychopharmacology (Berl) Date: 2022-10-22 Impact factor: 4.415
Authors: John P Dougherty; Brian S Wolff; Mary J Cullen; Leorey N Saligan; Marvin C Gershengorn Journal: Pharmacol Res Date: 2017-07-15 Impact factor: 7.658
Authors: Aaron J Grossberg; Elisabeth G Vichaya; Diana L Christian; Jessica M Molkentine; Daniel W Vermeer; Phillip S Gross; Paola D Vermeer; John H Lee; Robert Dantzer Journal: Cancer Res Date: 2017-12-07 Impact factor: 12.701
Authors: Amy E Perkins; Tamara L Doremus-Fitzwater; Robert L Spencer; Elena I Varlinskaya; Melissa M Conti; Christopher Bishop; Terrence Deak Journal: Exp Gerontol Date: 2016-01-23 Impact factor: 4.032
Authors: Kelly T Cosgrove; Rayus Kuplicki; Jonathan Savitz; Kaiping Burrows; W Kyle Simmons; Sahib S Khalsa; T Kent Teague; Robin L Aupperle; Martin P Paulus Journal: Brain Behav Immun Date: 2021-05-27 Impact factor: 19.227